Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Inflammatory Carcinoma|Recurrent Breast Inflammatory Carcinoma|Stage IV Breast Inflammatory Carcinoma
Interventions: DRUG: Eribulin Mesylate|DRUG: Grapiprant
Sponsor: M.D. Anderson Cancer Center